关键信息
-
基因名
BCA-1/CXCL13
- 应用
-
别名
Angie, BCA-1, B lymphocyte chemoattractant, CXC chemokine BLC, Small-inducible cytokine B13
-
种属
Human
-
表达系统
E. coli
-
标签
Tag Free
-
纯度
Greater than 97% as determined by SDS-PAGE.
-
蛋白编号
O43927
-
表达区间
23-109aa
-
蛋白长度
Partial
-
分子量
10.3 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
BCA-1, also known as CXCL13, is a chemokine that plays a critical role in the immune system by facilitating the migration of B cells to lymphoid tissues. It is primarily produced by lymphoid stromal cells and is essential for the organization of lymphoid follicles. The study of BCA-1/CXCL13 has gained significant attention due to its implications in various autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, where aberrant B cell accumulation in tissues contributes to disease pathology. Additionally, the role of BCA-1/CXCL13 in cancer biology, particularly in tumor microenvironments, has emerged as a pivotal area of research, as it may influence tumor progression and metastasis by modulating immune cell infiltration and activation. Recombinant BCA-1/CXCL13 protein is increasingly being utilized in research to dissect its biological functions, understand receptor interactions, and explore its potential as a therapeutic target. Moreover, manipulation of BCA-1/CXCL13 pathways could provide novel strategies for enhancing vaccine responses or developing immunotherapies. By elucidating the mechanisms through which BCA-1/CXCL13 operates, researchers aim to identify new intervention points for diseases characterized by dysregulated immune responses, thereby expanding therapeutic options and improving clinical outcomes.
